Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Iloperidone: A new drug for the treatment of schizophrenia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 15 Feb 2011

Arif Sally A, Mitchell Melissa M

Abstract excerpt

PURPOSE: The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed. SUMMARY: Iloperidone is an atypical antipsychotic that recently received marketing approval from the Food and Drug Administration for the acute treatment of schizophrenia. Iloperidone is a pure antagonist and the first antipsychotic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Isoxazoles

Share to Piperidines

Share to Polymorphism, Single Nucleotide

Share to Randomized Controlled Trials as Topic

Share to Schizophrenia

Source

Identifiers

PMID: 21289324
DOI: 10.2146/ajhp100079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Iloperidone: A new drug for the treatment of schizophrenia.PMID 21289324Read ↗

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.Semantic proximity Read ↗

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.Semantic proximity Read ↗

Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.Semantic proximity Read ↗

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.Semantic proximity Read ↗

Long-term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults with Schizophrenia: Pooled Post hoc Analyses of Two 12-month Extension StudiesSemantic proximity Read ↗

Pharmacogenomic and inflammatory determinants of antipsychotic-induced extrapyramidal toxicity in Egyptian patients with schizophrenia.Semantic proximity Read ↗

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.Semantic proximity Read ↗

Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.Semantic proximity Read ↗

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.